Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Osemitamab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Transcenta Holding
Deal Size : Undisclosed
Deal Type : Collaboration
Transcenta Collaborates with Agilent To Develop Companion Diagnostic for Osemitamab
Details : The collaboration aims to develop a CLDN18.2 companion diagnostic for phase III TST001 (osemitamab) with nivolumab and chemotherapy in patients with advanced gastroesophageal adenocarcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : Osemitamab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Transcenta Holding
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Abemaciclib,Tamoxifen Citrate
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Basilea Pharmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Based on results, Verzenio may require dose modification. Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. Advise patients of potential risk to a fetus and to use effective contraception.
Product Name : Verzenio
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Abemaciclib,Tamoxifen Citrate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Basilea Pharmaceutica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GI-101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : GI Innovation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The MOU establishes a framework in which the two companies will enter into a strategic partnership to explore potential genomic biomarkers of the tumor microenvironment in an early-phase trial of the investigational compound GI-101.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 02, 2020
Lead Product(s) : GI-101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : GI Innovation
Deal Size : Undisclosed
Deal Type : Collaboration
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
Details : NK Cell Enriched Donor Lymphocytes is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 25, 2015
Reset All
